Manatū Hauora | Ministry of Health. In June 2023, the Public Health Agency, within the Ministry of Health, commissioned research and evaluation agency Verian to undertake a series of research projects and population surveys into attitudes and behaviours related to...
Newsroom. The national drug-buying agency has been encouraged to re-think how it frames future pitches for funding increases in order to make them more compelling to ministers overseeing cost-cutting exercises across government. Read...
The aim of this study was to explore participants’ previous experiences with paying for medicines, and the impact of receiving free medicines through the Free Meds study
Health Committee. In accordance with the Government’s commitment to allow the sale of cold and flu medication containing pseudoephedrine, the purpose of this Bill is to change the classification of pseudoephedrine as a controlled drug. This Bill reclassifies...
Dew et al. We argue that for most people with long-term cancer survival wrangling is a social practice, but the capacity to succeed in that practice is dependent on a range of factors, including levels of economic, cultural, and social capital. Read...
Cabinet papers:
Allowing sales of cold medicines containing pseudoephedrine
Misuse of Drugs (Pseudoephedrine) Amendment Bill 2024: Approval for Introduction
New Zealand funds their medicine through PHARMAC, a crown entity that determines and negotiates which essential medicine will be funded with their limited budget. The budget, given by the NZ government, was 71 million for 2022 and 120 million for 2023. PHARMAC has...
NZ has a strong research basis to possibly accelerate the drug research and development industry - an industry that is going through rapid changes by outsourcing drug development to different countries.
Consistent with existing literature, we find that the level of frailty is significantly associated with the cost of healthcare. However, we find no association between drug burden and nonpharmaceutical/overall healthcare costs.
Four intermediate health service outcomes were identified: development of extended community pharmacist services; consumers using extended community pharmacist services; more integrated, collaborative primary health care services; and a fit-for-purpose community pharmacy workforce.
HEALTH SERVICES AND SYSTEMS
EQUITY
Exploring the impacts of the health system on minorities within the population, notably including Māori, Pacifica, Asians and LGBTQI.
DRUGS, DEVICE AND DIAGNOSTICS
PUBLIC HEALTH
DIGITAL HEALTH
TE TIRITI